InterVapor in the News

• Daily Mail, 2/28/12
  Steam Clean Your Lungs Back to Life
• Medical Technology Business Europe, 1/27/12
  First Patients Suffering From Severe Emphysema Treated With InterVapor
• MedGadget, 1/26/12
  The Future of InterVapor: A Q&A with Uptake’s Chief Medical Officer Steven Kesten
• NDR (Germany), 1/24/12
  New Treatments for COPD
  
• Medical Device Daily, 1/4/12
  Financings Roundup: Uptake Raises $35 million; Eyes InterVapor Approval
• Device Space 1/4/12
  Uptake Medical Raises $35 Million Cash for Novel Emphysema Treatment
• Ideas for Surgery, 12/31/11
  Uptake Medical’s Intervapor System For Severe Emphysema Treatment – Personalized Endoscopic Lung Reduction Procedure
• About.com COPD 12/23/11
  Uptake Medical Announces TGA Approval for InterVapor
• Medical Device Daily, 12/22/11
  Uptake Gets Australian Approval for InterVapor, Eyes U.S. Market
• Orange County Business Journal, 12/11/11
  Uptake Medical Progress Report
• Global Hospital Management 12/2/11
  Uptake Medical Treats First Patient with InterVapor System
• Medical Device Network 12/2/11
  Uptake Medical Treats First Patient with InterVapor System
• Medical Device Daily, 12/1/11
  NewCo on the Block: InterVapor Vows “No Implant Left Behind” in Emphysema Patients
• Medical Technology Business Europe, 9/29/11
  Uptake Medical InterVapor System for Emphysema Wins EU Approval
  

Uptake Medical will be showcasing the InterVapor® technology at the following conferences, trade shows and events:

2013

European Respiratory Society – Annual Congress 2013
Barcelona, Spain, Sep. 7-11, 2013

American Thoracic Society 2013 International Conference
Philadelphia, PA, May 17-22, 2013

2nd European Congress for Broncology and Interventional Pulmonology
Cesme-Izmir, Turkey, Apr. 27-30, 2013

54th Congress of the German Society for Pneumology and Respiratory Medicine
Hannover, Germany, Mar. 20-23, 2013

2012

European Respiratory Society – Annual Congress 2012
Vienna, Austria, Sep. 1-5, 2012

17th World Congress for Broncology and Interventional Pulmonology
Cleveland, OH, Jun. 15-18, 2012

American Thoracic Society 2012 International Conference
San Francisco, CA, May 18-23, 2012

TSANZ and ANZSRS Annual Scientific Meetings
Canberra, Australia, Mar. 30 – Apr. 4, 2012

53rd Congress of the German Society for Pneumology and Respiratory Medicine
Nuernberg, Germany, Mar. 29 – Apr. 1, 2012

Educational Symposium: Improving Outcomes in Patients with Severe Emphysema: The Introduction of InterVapor
Melbourne Convention & Exhibition Centre, Australia, Feb. 18, 2012
          To RSVP or for more information: intervapor@aurorabioscience.com.au

13th Annual Hands-On Thoracic Endoscopy Workshop
Heidelberg, Germany, Jan. 19-21, 2012

Press Releases

• May 23, 2012 – Uptake Medical Announces Positive 12-month Outcome Data for InterVapor Therapy for Severe Emphysema
• Jan. 9, 2012 – Uptake Medical Announces Successful Completion of Series C Financing
• Dec. 21, 2011 - Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema
• Nov. 29, 2011 – Uptake Medical Announces First Commercial Use of InterVapor for Patients with Severe Emphysema
• Sept. 26, 2011 – Uptake Medical Receives CE Mark for InterVapor – Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema – And Announces Positive Clinical Results
• Sept. 6, 2011 – Uptake Medical Expands Executive Team, Announces European General Manager Lloyd Mencinger
• March 1, 2011 – Uptake Medical Announces Scott Huennekens Elected to Board of Directors
• Nov. 1, 2010 – Steven Kesten, M.D., Leader in Pulmonary Medicine, Joins Uptake Medical as Vice President and Chief Medical Officer
• July 7, 2010 – Uptake Medical Completes Series B Financing Round for $17.5 Million
• Dec. 21, 2009 – Uptake Medical Announces First Patients Treated in Clinical trial for Patients with Heterogeneous Emphysema (the VAPOR trial)

Fact Sheet 

Media Contact:
Laura Jackson
+1.714.731.6761
laura@lmjpr.com